JPS63280019A - 悪性黒腫の治療に於けるｏｄｃ阻害剤ダカルバジン及びインターフェロンの使用 - Google Patents

悪性黒腫の治療に於けるｏｄｃ阻害剤ダカルバジン及びインターフェロンの使用

Info

Publication number
JPS63280019A
JPS63280019A JP63096971A JP9697188A JPS63280019A JP S63280019 A JPS63280019 A JP S63280019A JP 63096971 A JP63096971 A JP 63096971A JP 9697188 A JP9697188 A JP 9697188A JP S63280019 A JPS63280019 A JP S63280019A
Authority
JP
Japan
Prior art keywords
ornithine decarboxylase
interferon
decarboxylase inhibitor
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63096971A
Other languages
English (en)
Japanese (ja)
Inventor
サイ　ピー．サンカラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of JPS63280019A publication Critical patent/JPS63280019A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP63096971A 1987-04-23 1988-04-21 悪性黒腫の治療に於けるｏｄｃ阻害剤ダカルバジン及びインターフェロンの使用 Pending JPS63280019A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4189187A 1987-04-23 1987-04-23
US041,891 1987-04-23

Publications (1)

Publication Number Publication Date
JPS63280019A true JPS63280019A (ja) 1988-11-17

Family

ID=21918900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63096971A Pending JPS63280019A (ja) 1987-04-23 1988-04-21 悪性黒腫の治療に於けるｏｄｃ阻害剤ダカルバジン及びインターフェロンの使用

Country Status (11)

Country Link
EP (1) EP0288055B1 (enExample)
JP (1) JPS63280019A (enExample)
KR (1) KR880012239A (enExample)
AT (1) ATE78174T1 (enExample)
AU (1) AU609120B2 (enExample)
DE (1) DE3872749T2 (enExample)
DK (1) DK167905B1 (enExample)
ES (1) ES2051788T3 (enExample)
GR (1) GR3005553T3 (enExample)
IE (1) IE61498B1 (enExample)
ZA (1) ZA882719B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369944A1 (de) * 1988-11-18 1990-05-23 Ciba-Geigy Ag Substituierte Oxadiaminobutane
IL97759A0 (en) * 1990-04-11 1992-06-21 Ciba Geigy Ag Hydroxylamine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499072A (en) * 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4999072A (en) * 1987-10-19 1991-03-12 Milliken Research Corporation Method of making an insole product

Also Published As

Publication number Publication date
ES2051788T3 (es) 1994-07-01
DK167905B1 (da) 1994-01-03
KR880012239A (ko) 1988-11-26
DK222988D0 (da) 1988-04-22
IE61498B1 (en) 1994-11-02
AU1502388A (en) 1988-10-27
EP0288055A1 (en) 1988-10-26
GR3005553T3 (enExample) 1993-06-07
DE3872749T2 (de) 1992-12-03
DE3872749D1 (de) 1992-08-20
IE881221L (en) 1988-10-23
ZA882719B (en) 1988-10-17
ATE78174T1 (de) 1992-08-15
DK222988A (da) 1988-10-24
EP0288055B1 (en) 1992-07-15
AU609120B2 (en) 1991-04-26

Similar Documents

Publication Publication Date Title
CA1302270C (en) Carcinostatic agent
TW407055B (en) Pharmaceutical compositions for use in a photodynamic therapy for treating multiple sclerosis and rheumatoid arthritis
US4499072A (en) Process for treating diseases with ODC inhibitors
JPH0649651B2 (ja) 心筋虚血治療用医薬組成物
RU2002128917A (ru) Полиаминные аналоги в качестве цитотоксических агентов
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
US4883661A (en) Use of arginine as an lymphokine synergist
BE905198A (nl) Farmaceutische preparaten met vaatverwijdende en anti-anoxische werking.
JPS63280019A (ja) 悪性黒腫の治療に於けるｏｄｃ阻害剤ダカルバジン及びインターフェロンの使用
US6525035B1 (en) Therapeutic composition and methods
US5510390A (en) Anti-hypertensive composition and methods of treatment
US3326761A (en) 6-demethyl-6-deoxytetracycline, anti-tumor antibiotic
Schultz et al. Potentiation of nonspecific immunotherapy of experimental lung metastases by indomethacin
CA2489705A1 (en) Use of amide derivative of ge 2270 factor a3 for the treatment of acne
JP2003535891A (ja) 置換アクリロイルジスタマイシン誘導体及びアルキル化剤を含む腫瘍に対する併用療法
AU2001281867A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
US6482833B2 (en) Immunotherapeutic anti-cancer pharmaceutical compositions
JPS62263127A (ja) 自己由来のｌａｋ細胞、インタ−ロイキン−２、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置
US4521406A (en) Antitumor agent
JPS59130213A (ja) 抗腫瘍方法及び組成物
CA2077996C (en) Roquinimex for supportive use
Brunda et al. Interferon Alpha and Interleukin-2 on Tumor Metastases and Cytotoxic Cell Function
RU2006137699A (ru) Биологически активные производные пептида vapeehptllteaplnpk
WO1994002124A1 (fr) Agent anti-hiv
PH26698A (en) Method of potentiating natural killer cell activity